- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute myeloid leukaemia
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 582KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 105KB)
Daunorubicin with cytarabine – November 2023
Daunorubicin With Cytarabine: Powder for I.V infusion containing daunorubicin 44 mg and cytarabine 100 mg; Vyxeos®
Last updated
1 March 2024